Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil vs Nitroglycerin for Coronary Slow Flow in STEMI
NCT03296670Phase 4Completed
- Sponsor
- Renji Hospital
- Start
- Aug 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Vasostenoon in ST-elevation myocardial infarction (STEMI) and Coronary Slow Flow Phenomenon (CSFP), sponsored by Renji Hospital. Primary endpoints: TIMI Flow Grade (post-PCI) and TIMI Flow Grade (post-infusion). Started Aug 2015; status: completed.
02
Drugs
Vasostenoon
03
Conditions
ST-elevation myocardial infarction (STEMI)Coronary Slow Flow Phenomenon (CSFP)
Beyond the preview
Go deeper on NCT03296670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296670.